Fayez Sarofim & Co
NVO

Fayez Sarofim & Co’s Novo Nordisk NVO Stock Holding History

Fayez Sarofim & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125M Sell
3,395,479
-839,270
-20% -$39.8M 0.32% 54
2025
Q4 		$215M Sell
4,234,749
-3,118,838
-42% -$159M 0.52% 46
2025
Q3 		$408M Sell
7,353,587
-3,150,075
-30% -$184M 0.95% 30
2025
Q2 		$725M Sell
10,503,662
-708,837
-6% -$48.2M 1.74% 17
2025
Q1 		$779M Sell
11,212,499
-171,982
-2% -$14.2M 1.94% 16
2024
Q4 		$979M Sell
11,384,481
-832,637
-7% -$90M 2.38% 9
2024
Q3 		$1.45B Sell
12,217,118
-334,970
-3% -$44.7M 3.7% 4
2024
Q2 		$1.79B Buy
12,552,088
+736,251
+6% +$97.6M 4.83% 3
2024
Q1 		$1.52B Buy
11,815,837
+1,786
+0% +$213K 4.52% 3
2023
Q4 		$1.43B Buy
11,814,051
+210,087
+2% +$20.8M 4.38% 3
2023
Q3 		$1.06B Buy
11,603,964
+1,364,594
+13% +$120M 3.56% 6
2023
Q2 		$829M Sell
10,239,370
-321,344
-3% -$26.3M 2.9% 7
2023
Q1 		$840M Buy
10,560,714
+327,976
+3% +$23.3M 2.94% 8
2022
Q4 		$692M Sell
10,232,738
-203,470
-2% -$11.9M 2.56% 8
2022
Q3 		$520M Buy
10,436,208
+900,560
+9% +$48.2M 2.05% 13
2022
Q2 		$531M Buy
9,535,648
+1,322
+0% +$73.4K 1.94% 14
2022
Q1 		$529M Sell
9,534,326
-130,034
-1% -$6.67M 1.67% 19
2021
Q4 		$541M Sell
9,664,360
-180,188
-2% -$9.76M 1.62% 18
2021
Q3 		$473M Sell
9,844,548
-17,176
-0.2% -$830K 1.56% 20
2021
Q2 		$413M Sell
9,861,724
-68,986
-0.7% -$2.67M 1.39% 23
2021
Q1 		$335M Sell
9,930,710
-36,184
-0.4% -$1.29M 1.23% 30
2020
Q4 		$348M Sell
9,966,894
-33,460
-0.3% -$1.16M 1.34% 27
2020
Q3 		$347M Sell
10,000,354
-125,740
-1% -$4.19M 1.49% 24
2020
Q2 		$332M Buy
10,126,094
+1,676,222
+20% +$53.5M 1.53% 22
2020
Q1 		$254M Sell
8,449,872
-359,328
-4% -$10.7M 1.56% 24
2019
Q4 		$255M Sell
8,809,200
-230,448
-3% -$6.38M 1.23% 32
2019
Q3 		$234M Buy
9,039,648
+69,692
+0.8% +$1.76M 1.2% 31
2019
Q2 		$229M Buy
8,969,956
+27,452
+0.3% +$678K 1.18% 32
2019
Q1 		$234M Buy
8,942,504
+21,884
+0.2% +$538K 1.23% 29
2018
Q4 		$205M Buy
8,920,620
+3,930
+0% +$87.3K 1.24% 28
2018
Q3 		$210M Sell
8,916,690
-77,230
-0.9% -$1.88M 1.1% 31
2018
Q2 		$207M Sell
8,993,920
-288,996
-3% -$6.87M 1.12% 30
2018
Q1 		$229M Sell
9,282,916
-189,888
-2% -$4.99M 1.24% 28
2017
Q4 		$254M Sell
9,472,804
-595,354
-6% -$15.1M 1.32% 26
2017
Q3 		$242M Sell
10,068,158
-154,624
-2% -$3.49M 1.27% 26
2017
Q2 		$219M Sell
10,222,782
-347,122
-3% -$7M 1.17% 26
2017
Q1 		$181M Sell
10,569,904
-592,688
-5% -$10.3M 0.99% 32
2016
Q4 		$200M Sell
11,162,592
-592,724
-5% -$10.7M 1.1% 28
2016
Q3 		$244M Sell
11,755,316
-380,772
-3% -$9.44M 1.33% 23
2016
Q2 		$327M Buy
12,136,088
+253,658
+2% +$6.96M 1.79% 12
2016
Q1 		$322M Sell
11,882,430
-190,558
-2% -$5.11M 1.85% 11
2015
Q4 		$350M Sell
12,072,988
-477,628
-4% -$13.2M 2.02% 10
2015
Q3 		$341M Sell
12,550,616
-306,484
-2% -$8.68M 1.97% 11
2015
Q2 		$353M Sell
12,857,100
-543,208
-4% -$15.3M 1.79% 13
2015
Q1 		$359M Buy
13,400,308
+87,566
+0.7% +$2.02M 1.76% 12
2014
Q4 		$282M Sell
13,312,742
-201,426
-1% -$4.5M 1.34% 19
2014
Q3 		$322M Sell
13,514,168
-26,912
-0.2% -$619K 1.5% 17
2014
Q2 		$313M Sell
13,541,080
-487,942
-3% -$10.8M 1.43% 22
2014
Q1 		$320M Sell
14,029,022
-445,428
-3% -$9.49M 1.52% 18
2013
Q4 		$267M Buy
+14,474,450
New +$252M 1.24% 25
2013
Q2 		$232M Buy
+14,989,150
New +$249M 1.17% 28

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co's NVO Position: Q1 2026 in Review

Fayez Sarofim & Co reduced its Novo Nordisk (NVO) stake by 20% in Q1 2026, selling an estimated $39.8M and leaving 3,395,479 shares worth $125M. The position accounts for 0.32% of the portfolio, ranked #54.

Fayez Sarofim & Co first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.79B in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Fayez Sarofim & Co held 3,395,479 shares of Novo Nordisk worth $125M as of Q1 2026.
  • Fayez Sarofim & Co sold 839,270 Novo Nordisk shares in Q1 2026, an estimated $39.8M.
  • Novo Nordisk made up 0.32% of Fayez Sarofim & Co's portfolio in Q1 2026, its #54 holding.
  • Fayez Sarofim & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
  • Fayez Sarofim & Co's Novo Nordisk position peaked at $1.79B in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.